argenx SE (ARGNF)

Market Cap	54.89B
Revenue (ttm)	3.68B
Net Income (ttm)	1.53B
Shares Out	n/a
EPS (ttm)	23.27
PE Ratio	35.80
Forward PE	31.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108
Average Volume	13
Open	870.00
Previous Close	872.27
Day's Range	870.00 - 870.00
52-Week Range	532.40 - 872.27
Beta	-0.11
RSI	72.38
Earnings Date	Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,599
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARGNF